| Bioactivity | Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the treatment of inflammatory diseases. It is a new, effective and selective inhibitor of mPGES-1 with an IC50 value of 0.42 μM. |
| Name | BRP-201 |
| CAS | 2227434-74-2 |
| Formula | C28H27ClN4OS |
| Molar Mass | 503.06 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ergül AG, et al. Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase. Eur J Med Chem. 2022 Mar 5;231:114167. |
BRP-201
CAS: 2227434-74-2 F: C28H27ClN4OS W: 503.06
Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the treatm
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.